Vadodara: Alembic Pharma has announced that the Company has successfully completed
the United States Food and Drug Administration (USFDA) inspection for its API-III
Facility located at Karakhadi.”This was a scheduled GMP inspection and was
successfully completed without any Form 483 observation,” the Company stated in a BSE filing. The inspection was
conducted from 17th March, 2025 to 21st March, 2025.Read also: Alembic Global Holding incorporates wholly-owned subsidiary in USAAlembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: Alembic Pharma bags USFDA final approval for schizophrenia drug Brexpiprazole